The paradigm for treating excess weight is shifting from lifestyle-first to medication-first approaches, fundamentally changing how clinicians conceptualize obesity care. This evolution recognizes obesity as a complex metabolic disorder requiring pharmaceutical intervention rather than purely behavioral modification. The dual GIP/GLP-1 receptor agonist tirzepatide emerges as the most effective option, delivering weight reductions exceeding 20% in select patients—results that approach surgical outcomes without invasive procedures. Semaglutide and liraglutide, single-pathway GLP-1 agonists, demonstrate substantial but comparatively modest effects. These incretin mimetics work by slowing gastric emptying, enhancing satiety signaling, and modulating reward pathways in the brain that drive food-seeking behavior. The clinical impact extends beyond weight reduction: patients with cardiovascular disease, sleep apnea, and metabolic syndrome experience meaningful improvements in their underlying conditions. However, this therapeutic revolution faces significant implementation barriers that limit real-world impact. Prescriber hesitancy stems from unfamiliarity with these newer agents and concerns about long-term safety profiles. Insurance coverage remains inconsistent, creating access disparities that particularly affect lower-income populations who face the highest obesity rates. The economic burden of monthly costs exceeding $1,000 for many patients represents a fundamental healthcare equity challenge. As multiple next-generation obesity medications advance through clinical trials, the field appears poised for continued innovation. Yet the ultimate success of pharmacological obesity management depends less on drug development than on systematic changes to healthcare delivery, insurance policies, and physician education programs.